Our Goal

Metha Biofund is a funding platform which objective is to bypass big corporations and governments interests in the domain of medical, biological and biotechnological research. With a special emphasis (but not limited to it) in anti-aging research. The purpose of Metha is to provide a funding platform which goal is to extend human lifespan by an order of magnitude. While the objective is very far away, we are sure that the road to it is paved with hundreds of successful investigations which can bring new treatments, cures, and therapies that will help millions of people worldwide. Those eventual discoveries and patents will for sure in the long run extend the lifespan of human beings and bring value to all the people that joined the dream to help humanity go beyond life.

Blockchain technology brings the power to shape the future we always dreamed of by eliminating the final bond that humanity imposed to itself.
This document is for informational purposes only and does not constitute an offer or solicitation to sell shares or securities in METHA BIOFUND or any related associated company. Any such offer or solicitation will be made only by means of a confidential offering memorandum and in accordance within the terms of all applicable laws and regulations.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>6</td>
</tr>
<tr>
<td>The current situation of medical research</td>
<td>6</td>
</tr>
<tr>
<td>The problem</td>
<td>7</td>
</tr>
<tr>
<td>The solution</td>
<td>7</td>
</tr>
<tr>
<td>The Metha platform</td>
<td>8</td>
</tr>
<tr>
<td>Quick Rundown</td>
<td>8</td>
</tr>
<tr>
<td>Example use cases</td>
<td>8</td>
</tr>
<tr>
<td>Metha token Crowdsale</td>
<td>10</td>
</tr>
<tr>
<td>The Crowdsale</td>
<td>10</td>
</tr>
<tr>
<td>How to Contribute</td>
<td>12</td>
</tr>
<tr>
<td>Token Utility and Functionalities</td>
<td>12</td>
</tr>
<tr>
<td>Contributor Support and Troubleshooting</td>
<td>13</td>
</tr>
<tr>
<td>Distribution of Crowdsale Funds</td>
<td>14</td>
</tr>
<tr>
<td>Escrow</td>
<td></td>
</tr>
<tr>
<td>Marketing Strategy and Branding</td>
<td>17</td>
</tr>
<tr>
<td>Importance of a marketing campaigns</td>
<td>17</td>
</tr>
<tr>
<td>Marketing team</td>
<td>17</td>
</tr>
<tr>
<td>Partnership Agreements</td>
<td>18</td>
</tr>
<tr>
<td>Why Partnerships?</td>
<td>18</td>
</tr>
<tr>
<td>Being a Metha partner</td>
<td>18</td>
</tr>
<tr>
<td>How can I be a Metha Biofund partner?</td>
<td>18</td>
</tr>
<tr>
<td>Open Metha Platform</td>
<td>19</td>
</tr>
<tr>
<td>What is the Open Metha Platform (OMP)?</td>
<td>19</td>
</tr>
<tr>
<td>How it works?</td>
<td>19</td>
</tr>
<tr>
<td>Development of OMP</td>
<td>20</td>
</tr>
<tr>
<td>Risks</td>
<td>21</td>
</tr>
<tr>
<td>Immaturity of The Ethereum Technology</td>
<td>21</td>
</tr>
<tr>
<td>Unknown Impact of Proposed Changes to Ethereum</td>
<td>21</td>
</tr>
<tr>
<td>Prohibitively High Gas Prices For Transactions</td>
<td>21</td>
</tr>
</tbody>
</table>

Error! Bookmark not defined.
Ethereum May be Superseded 22
Blockchain Risk 22
Risk of Theft or Misuse of Private Keys 22
New Technology 22
Competition 23
Business Execution Risks 23
Project Completion 23
Ability to Transact or Resell 23
Token Security 24
Access to Private Keys 24
Exchange and Counterparty Risks 24
Uncertain Regulatory Framework 24
Currency Regulation Risks 25
Risk of Government Action 25
Risks Associated with the Token Sale 25
Taxation Risks 26
Capital Control Risks 26
CTF and Anti-Money Laundering Regulations 26

Legal Considerations 27
Disclaimer 27
Disclaimer "forward looking statements" 27
Introduction

The current situation of medical research

In the last century we have witnessed the explosion of scientific advances in many domains, the socio-economic situation of the world led to a competitive environment in which countries and corporations had the means and the will to invest in scientific research. This golden era changed the world drastically and improved the life of the future generations, which now can enjoy the best time in human history.

We have seen the possibility to make a trip around the world in a matter of hours, we made it to the moon, we invented near instant communication, we learnt how to grow plants that we designed. Almost every domain of human life has seen an improvement of several orders of magnitude. Except one. Lifespan. While it has improved it has not seen the same growth as everything around it.

This scientific trend also led people to use the discoveries to their own purpose. With some analytic tools and marketing studies, research has now become a tool to produce wealth. This has led to a situation where some patented treatments or solutions to diseases or health problems will not be produced nor distributed to the general public for the sole reason that they are not profitable, or because they make other more expensive treatments obsolete.
The problem
The fact is that there is a conflict of interest in the medical domain. The multimillionaire corporations and companies that produce medicaments or treatments gain their wealth based on demand of sick people. Therefore, it is in their interest to not research for real solutions to diseases because if diseases disappear so does their profit, instead they fund and produce palliative products which in most cases have placebo and doubtful effects and that do not get to the roots of the problem (like anti-aging creams, pills…). The other big actor that could afford the cost of researching in augmenting human lifespan is governments, which also have a conflict of interest when doing so. If population gets older, they cannot afford to have a big part of their population to not be active and produce wealth, but instead to be a burden to their finances.

The solution
Blockchain technology brings the power to individuals worldwide to gather their financial powers to fund, develop, and accomplish projects that neither corporations nor governments have the will or the necessity to get involved with.

For the first time in history, human individuals have the power to choose what matters to them and make it happen. Specially in the research domain, where we already have the means to exchange information instantly to make the world one giant laboratory, we now have the means of funding that research to what matters the most for individuals, which in many cases is to live a long and healthy life for ourselves and the people we love.
Quick Rundown
To engage in this endeavor we introduce the blockchain based Metha funding platform. Metha will setup a crowdsale of a cryptographic Token on the Ethereum network, which will allow everyone around the globe with an internet connection to participate, sending ether(ETH) to the smartcontract.

In return contributors will get METHA (METH) tokens which possession will allow exclusive access to treatments, medicaments, and therapies discovered and patented by the research funded by the crowdsale.

The ETH contributed will be distributed between the associate universities, private labs, and research facilities which adhere to our system to get the funding they need to keep up their good work. Metha Biofund will also deploy their own research and production facilities, interconnecting all the partner laboratories to share critical data and setting up a global research forum to help hasten discoveries by sheer teamwork. A part of the funding will also be destined to support young talents worldwide to attract them to get ready to work as a productive member of this ecosystem, increasing this way the manpower behind research.

Last but not least, Metha Biofund will setup a public free to use platform to submit patents, research lines or ideas that need funding, so people can hand pick the scientific projects they desire to invest in, funding powered by the METH token.

Example use cases
- Martin, believes in Metha Biofund Vision and decides to contribute 0.2 ETH to the crowdsale. His ETH combined to the ether of many other people like him go to fund a research project at University Of California at Los Angeles that 5 years later finds a cure to all sorts of pancreatic cancers. Martin brother gets the chance to live longer when at age 70 he is found to have pancreatic cancer, extending his lifespan to 110 years. In the mean time a private lab which also received funds from Metha developed a way to regenerate cartilage, improving significantly his quality of life.

- Sarah sees the potential increase in value of the METH token as partnerships between Metha and research labs manifest, or when new
discoveries start to arise. Therefore, as an inversion she decides to support the Metha Project.

- Jim is an individual scientist that finds a better way for earlier detection of some sorts of cancer. Jim can’t get his patent to production because pharma corporations would lose millions in sales of treatments for said sorts of cancer. Jim decides to adhere the Metha Funding platform as a partner and finally gets his product to the wide public, in which eventually Martin and Sarah get their diseases detected way before they become a threat to their life, further expanding their lifespan.

- Beth is a talented biology student but is unsure that a life dedicated to research may provide enough for her to grow a family in the future. Metha Biofund supports her career so she can focus in finishing her studies related to anti-aging research and work in what she likes the most.

- John is leading a private research lab that looks for an effective antibaladness treatment, he chose to use Metha Public Platform to submit his project, and offer shares of his patent via ICO to people that help him achieve his funding goal of 1000 ETH.

- Laura’s son needs a treatment for a nervous disease, which cure was discovered by a Metha Biofund partner. Laura’s insurance covers all the expenses by acquiring for her on the market or on the crowdsale the METHA tokens needed to access the treatment for her son.

- Carl goes to his local pharmacy to purchase the pills produced by Metha Biofund for his treatment, part of the profits gets back into the platform to keep funding awesome projects.
Metha token Crowdsale

The Crowdsale

Metha biofund token crowdsale is designed to last as long as the utopic objective of Metha Biofund is not achieved. Inspired in the EOS token sale contract, a set amount of tokens will be sold at every period of 23 hours independently of the ether contributed during that period. Which means all the tokens of any given period will be distributed among the contributors of that period regardless of the total ether contributed.

The number $n$ of METH tokens distributed to a contributor is calculated as follows:

$$n = \frac{a \cdot b}{c}$$

Where

- $a = \text{‘Total ETH sent by the contributor during the period’}$
- $b = \text{‘Total number of METH Tokens available for distribution in the period’}$
- $c = \text{‘Total ETH contributed by all contributors during the period’}$
Let’s see a quick example:

20 METH Tokens are available during a period.

Cris contributes 4 ETH.
Alice contributes 1 ETH.
The period ends.

As a total of 5 ETH were contributed for 20 METH Tokens during the period, 1 METH Token will be distributed for every 0.25 ETH contributed.

Therefore, Cris receives 16 METH Tokens and Alice receives 4 METHT Tokens.
The daily total of tokens may be subject to revisions based on, demand of the token, circulating supply, punctual funding campaigns... The objective is that in the long run the volume of the "minted" tokens every period will remain negligible before the daily token transactions.

All the code is open source and can be revised by everyone whether by exploring the Ethereum blockchain or at our Github Public Repository. The code is also freeware and is free to be used with or without modification for any other project. All code will be audited and inspected carefully to ensure the security and correct functioning of the contract. However, given the fact that the token and token sale will be lasting for a long period of time, vulnerabilities in the Ethereum network and in the code of the token sale itself may be exposed. In this event, the token has a security feature which in the exposure of a high risk vulnerability will freeze token transfers. Tokens will then be replaced by a revised version without said vulnerability and distributed to holder addresses before the vulnerability was exposed. If you find any kind of vulnerability in the code of the crowdsale, the token or Ethereum blockchain itself please get in touch with us at metha@metha.life to claim your bounty for helping us improve and secure the project.

**How to Contribute**

To contribute to the crowdsale just send the ether you want to contribute to the token contract, after the period in which you contributed ends, you can claim your tokens at any time whether by calling the claimDay function to claim the tokens of a specific day, or the claimAll to claim all periods at once. Bear in mind that the claimAll function is gas expensive, and it may be better if you contributed in a few days to just call every day individually.

You can also use the buyWithLimit function to set a maximum ether price per token for your contribution to be submitted, we recommend using this method to ensure you will not pay more than you expect for your tokens. If the closing period price is higher than what you set, ether will be refunded.

Alternatively a step by step screenshot guide on how to contribute to the crowdsale can be found in our website [https://metha.life](https://metha.life).

**Token Utility and Functionalities**

METH tokens are ERC-20 compatible tokens distributed on the Ethereum blockchain pursuant to a related ERC-20 smart contract (the “METH Tokens”).
METH tokens will grant privileged access to any patented treatment, cure, medicament or therapy discovered by the research funded by Metha Biofund and its partners. Also serving as a method of payment for their cost.

**Contributor Support and Troubleshooting**

If you have trouble using the crowdsale, the tokens, or have any kind of suggestion or inquiry related to Metha Biofund please get in touch with us at support@metha.life. Metha team will be happy to assist you.
Fund Managing

Distribution of Crowdsale Funds

Here are some examples of fund distribution:

- **Metha Research**: Funding for anti-aging research including, degenerative diseases and syndromes related to aging, genetic therapies, nanotechnology, biotechnology, Oncologic research... The funds will be distributed to universities, private or public laboratories or foundations that wish to become Metha Biofund partners to get the funding they need. Metha will also put in place their own research facility and database platform where all partners can exchange info on the road to improve human lifespan.

- **Metha Pharma**: Funding for the manufacturing of medicaments, treatments, and research materials and consumables, by Metha Pharma or Associated Manufacturers.

- **Metha Managing**: Funding for the building, maintenance and running of Metha Biofund, for its hiring costs, legal expenses, and profits. Allowing for the development of the Open Metha Platform, marketing schemes, strategy analysis, partner negotiations...

- **Metha Student Support**: Funding to sponsor young talented students to encourage them to make their career in the anti-ageing research world.
This is the ideal funding distribution however, the needs of the project may vary as the time goes by, and success of the project may also have ups and downs which might alter the flow of funding and that will need special adjustments to the distribution. Two special cases are:

- The genesis of the project, where no funding is yet needed to manufacture medicaments, but where the key to the success of the project is to build all the infrastructure of Metha Biofund, by hiring, searching new partners who may need the funding, getting legal assistance to protect the project, and paying for the first marketing campaigns to attempt mass awareness. During the forge period of Metha Biofund the distribution will be as follows:

- When a relevant discovery leads to a patent for a heavy demanded treatment. In this case we may need to boost Metha Pharma funds for manufacturing according to demand. An example would be as follows:
Decentralized Fund Managing

We believe Compliance and building trust is key for success of this project, even though we plan to keep a constant dialog and updates between contributors and Metha about every day to day aspect of the project, we believe that using an autonomous decentralized system to distribute the funds is the best solution. Two possibilities arise.

- **AUDITING POOL:** The creation of a pool of auditors from various domains (researchers, tech lawyers, finance…). Every time a new project is candidate for funding, the system will randomly select some experts from the pool through the ETH chain, making sure that auditors will not always be the same and that decision is not corrupted. Auditors will then cast their take on the project and the Metha smart-contract will decide how much funding (if any) will be delivered to the project, based on expert’s vote.

- **NEURAL NETWORK:** The creation of a neural network capable of deciding fund distribution based on past data from failed and successful research, team composition of the projects, reliance on past research to conduct new experiments, and general research good practices.
Marketing Strategy and Branding

Importance of a marketing campaigns
As we saw in fund distribution, a percentage of funds will go to Metha management which includes the marketing department. We believe that reaching more people is of extreme importance. By looking for mass awareness we will bring more contributors to the platform which will lead to more funds for research and a faster pace of results, which will also lead to a better valuation of the project and the METH token.

Marketing investment will be constant as it is a pillar not only to bring more people to contribute but also to build trust and for branding purposes. However, punctual campaigns with increased inversion in marketing are also scheduled with the objective to boost the project at key times, for example when a notorious partnership is announced, or at genesis period.

Marketing team
Metha will hire an expert marketing team to lead a multilevel branding campaign, which main objective is to build trust in Metha Biofund brand, and to attract more contributors.

We plan to have a full scale presence in both crypto world and science and research. To achieve that we expect to be very active on social media with the help of community managers, generate and sponsor news content on the well known existing platforms for diffusion on both domains. We also aim to be present and active in conventions and make some appearances in mass media, following to punctual campaigns.

The multilevel marketing will have the following coverage:
Partnership Agreements

Why Partnerships?
We believe that there are many good research projects out there already in place, with talented, good working people trying their best. Metha doesn’t want to be a closed entity which only works by itself. The research to increase human lifespan is an ambitious project that involves every living human being in the planet and as so, we believe it can only be achieved by teamwork keeping aside selfish attitudes.

Being a Metha partner
By being a Metha partner, research institutions will have access to Metha funding. They will also have access to Metha research database and labs where they will be able to work together with other partners and metha itself to give another layer to research complexity and help each other to hasten results. Being a Metha partner also grants discounted access to Metha Pharma production, to provide them with all the tools and consumables they need for their research.

The only responsibility a Metha partner has is to help sustain Metha Biofund by agreeing to the uses and rights the METH token gives to contributors. This will be formalized by the signing of Metha terms and conditions and will be reviewed to each individual case and needs.

In case a project already received private funding prior to Metha partnership, METH tokens will be issued for the value of said funding upon proof of it. The partner will be responsible to distribute the tokens evenly to its prior contributors. In the event of having to issue tokens for a value over 10% of daily transaction volume of the Token, the issuance of tokens will be split in a certain time frame to not alter the value of the METH token.

How can I be a Metha Biofund partner?
In many cases we will be contacting the projects we believe to be most critical in the pursuit of our goal, however if you think your project adds value to Metha project and wish to work with us in this exciting adventure submit a request at partners@metha.life we will be pleased to consider your application and get back to you as soon as possible to know more about your project. If your project doesn’t fit Metha research leads, consider using our Open Metha Platform, Where health projects non related to anti-aging research can fulfill their needs by submitting their project and amount of funding requested.
What is the Open Metha Platform (OMP)?
OMP is a nest for all kinds of health-related, or quality of life improving projects or patents that struggled to have the funding they needed.

How it works?
Researchers and Inventors can submit their project to OMP with a detailed explanation of what problems it solves, what is the state of the research or patent, the funding they need, and what does the contributor get in return (standard METH token agreement, patent shares, profit shares, company shares...)

Upon revision of the project submitted, Metha will add the project to OMP.

People then can decide to contribute to their project if they like the idea, if the funding goal is met upon the ending of a certain period to be determined, Metha will act as an escrow for the project, and will deliver funds to the project manager upon revision that they will be used for what they were meant to.

In the case the funding goal for a given project is not met, Metha will refund contributors.
Development of OMP

OMP development will include a dev team to build a web, android and iOS app where everyone can keep track of the latest Metha news, the Open Metha projects, make contributions and receive support.
Risks

The risks associated with purchasing METH tokens are numerous and significant. In this section, we highlight some of the major known risks associated with METH.

**Immaturity of The Ethereum Technology**

The Ethereum blockchain is at an early stage of development and it is not fully known whether the Ethereum blockchain will be able to sustain long-term operations such as the METH crowdsale. As recently as June 2017, the Ethereum blockchain experienced significant delays in processing block transactions due to extremely high volumes associated with similar token sales around that time. It is not certain whether the Ethereum development community will resolve these technical issues in the future.

**Unknown Impact of Proposed Changes to Ethereum**

The Ethereum Foundation has laid out a roadmap for the improvement and development of Ethereum. While some of the future proposals offer promises to known technical issues, it is uncertain when these new improvements will be introduced, and whether they will be successful. In particular, proposals to "shard" the blockchain in order to greatly increase blockchain speeds is, at the time of publication, far from implementation. A proposal to change the mining process from the current Proof-of-Work algorithm to a Proof-of-Stake algorithm will have a yet to be seen impact for the Ethereum network.

**Prohibitively High Gas Prices For Transactions**

All transactions over the Ethereum blockchain, including the transfer of METH have a real-world cost in ETH ("Gas"). While at this point in time, Gas prices for basic transactions over the Ethereum network are nominal, there is no certainty that Gas prices will not increase, and thereby make the trading of METH over the Ethereum network commercially unfeasible. In addition, high volumes could lead to very high Gas prices for processing transactions, which made using the blockchain prohibitively expensive.
**Ethereum May be Superseded**

While today, in our view, the Ethereum blockchain technology presents the most promising advances in blockchain technology, there is no guarantee that Ethereum will not be supplanted by competing protocols that improve upon the Ethereum technology. The Ethereum technology is open-source, meaning that anyone can copy and disseminate the same code with modifications. It is not known whether the Ethereum platform will become the predominant protocol adopted by global industry. If Ethereum is surpassed or superseded, then this could impact the METH program as usage and adoption declines.

**Blockchain Risk**

On the Ethereum blockchain, timing of block production is determined by proof of work so block production can occur at random times. For example, ETH contributed to the METHA token sale smart contract (the "Metha Token Sale") in the final seconds of a distribution period may not get included for that period. You acknowledge and understand that the Ethereum blockchain may not include your transaction at the time you expect, and you may not receive METH the same day you send ETH. The Ethereum blockchain is prone to periodic congestion during which transactions can be delayed or lost. You acknowledge and understand that Ethereum block producers may not include your transaction when you want, or your transaction may not be included at all. Individuals may also intentionally spam the Ethereum network in an attempt to gain an advantage in purchasing cryptographic tokens.

**Risk of Theft or Misuse of Private Keys**

The control of the METHA source code resides within Metha Biofund Company which holds the requisite private keys in cold storage. While all reasonable measures may be implemented to prevent unauthorized use of the private keys, there is no certainty that the private keys will not be subject to theft, fraud or misuse. The unauthorized use of the private keys could result in significant disruption to METHA, and in a worst-case scenario, cause METHA to be unusable and therefore worthless.

**New Technology**

The METHA System and all of the matters set forth in this whitepaper are new and untested. The METHA System might not be capable of completion, implementation or adoption according to the development roadmap laid out in this whitepaper. Even if the METHA System is completed, implemented and adopted, it might not function as intended, and any tokens associated with the METH System may not have the functionality that is desirable or valuable. Also,
technology is changing rapidly, so METHA and any tokens transferable on the Ethereum Blockchain may become outdated.

**Competition**

While other blockchain solutions to medical and medical insurance have been proposed, as of the time of publication of this whitepaper Metha Biofund is not aware of any competition or similar projects. However, competition may manifest in the future with similar projects, and it is unsure what effect will this have for Metha Biofund and the METHA token value.

**Business Execution Risks**

The implementation of the Metha Biofund roadmap and deployment of its related technological components requires a high degree of professional business and software engineering experience. While the developers have a proven track-record of software engineering and business development, it is not certain whether the developers can fully deliver on the technical milestones set forth in the roadmap.

**Project Completion**

The development of Metha Biofund may be abandoned for a number of reasons, including, but not limited to, lack of interest from the public, lack of funding, lack of commercial success or prospects, or departure of key personnel.

**Ability to Transact or Resell**

You may be unable to sell or otherwise transact in METH at any time, or for the price you paid. By using the ERC-20 GATCOIN token contract (the "Smart Token Contract") or the Smart Sales Contract (collectively, the "Smart Contracts") or by purchasing METH, you acknowledge, understand and agree that: (a) METH tokens may have no value; (b) there is no guarantee or representation of liquidity for METH; and (c) Metha Biofund and its affiliates are not and shall not be responsible for or liable for the market value of the METH token, the transferability and/or liquidity of the METH token and/or the availability of any market for METH through third parties or otherwise.
Token Security
METH tokens may be subject to expropriation and/or theft. Hackers or other malicious groups or organizations may attempt to interfere with the Smart Contracts or METH in a variety of ways, including, but not limited to, malware attacks, denial of service attacks, consensus-based attacks, Sybil attacks, smurfing and spoofing. Furthermore, because the Ethereum platform rests on open source software and METH tokens and crowdsale are based on open source software, there is the risk that Ethereum smart contracts may contain intentional or unintentional bugs or weaknesses which may negatively affect METH tokens or result in the loss of your METH, the loss of your ability to access or control your METH or the loss of ETH in your account. In the event of such a software bug or weakness, there may be no remedy and holders of METH are not guaranteed any remedy, refund or compensation besides the application of the METH token security feature described in this document.

Access to Private Keys
METH purchased by you may be held by you in your digital wallet or vault, which requires a private key, or a combination of private keys, for access. Accordingly, loss of requisite private key(s) associated with your digital wallet or vault storing METH will result in loss of such METH, access to your METH Token balance and/or any initial balances in blockchains created by third parties. Moreover, any third party that gains access to such private key(s), including by gaining access to login credentials of a hosted wallet or vault service you use, may be able to misappropriate your METH. Metha Biofund is not responsible for any such losses.

Exchange and Counterparty Risks
If you send ETH to the Crowdsale Smart Contract from an exchange or an account that you do not control, pursuant to the Crowdsale Smart Contract, GAT will be allocated to the account that has sent ETH, therefore, you may never receive or be able to recover your METH. By using the Smart Contracts and/or by purchasing METH, you acknowledge and agree that you send ETH to the METH Token Sale Contract through an exchange account and/or hold METH on a cryptocurrency exchange or with another third party at your own and sole risk.

Uncertain Regulatory Framework
The regulatory status of cryptographic tokens, digital assets and blockchain technology is unclear or unsettled in many jurisdictions. It is difficult to predict how or whether governmental authorities will regulate such technologies. It is likewise
difficult to predict how or whether any governmental authority may make changes to existing laws, regulations and/or rules that will affect cryptographic tokens, digital assets, blockchain technology and its applications. Such changes could negatively impact METH in various ways, including, for example, through a determination that METH are regulated financial instruments that require registration. Metha Biofund may cease the distribution of METH, the development of the GAT System or cease operations in a jurisdiction in the event that governmental actions make it unlawful or commercially undesirable to continue to do so.

Currency Regulation Risks
Governments are still grappling with public policy on the regulation of cryptocurrencies as a form of settlement in trade. Governments adverse to the proliferation of the use of cryptocurrencies in local commerce could issue laws and regulations deeming the use of cryptocurrencies a regulated activity. This could result in holders of METH being unable to use their METH without further regulatory compliance by Metha Biofund.

Risk of Government Action
As noted above, the industry in which the company operates is new, and may be subject to heightened oversight and scrutiny, including investigations or enforcement actions. There can be no assurance that governmental authorities will not examine the operations of Metha Biofund and/or pursue enforcement actions against Metha Biofund. Such governmental activities may or may not be the result of targeting Metha Biofund in particular. All of this may subject Metha Biofund to judgments, settlements, fines or penalties, or cause company to restructure its operations and activities or to cease offering certain products or services, all of which could harm Metha Biofund’s reputation or lead to higher operational costs, which may in turn have a material adverse effect on the METH token and/or the development of Metha Biofund.

Risks Associated with the Token Sale
METH tokens are not investment products. Rather, METH tokens serve a specific function within the METH System, which is the means to access patented treatments cures or medicaments. Without METH, the general public may not get access to patented treatments, cures or medicaments discovered by Metha Biofund and its partners. There is also no expectation of future profit or gain from the acquisition of METH. METH do not represent (i) any equity or other ownership interest in Metha Biofund, (ii) any rights to dividends or other distribution rights
from Metha Biofund or (iii) any voting or other governance rights in Metha Biofund. For these and other reasons, we believe the sale of METH does not constitute a public offering of securities subject to prospectus registration requirements. However, public policy towards token sales is changing, and it is conceivable that regulators may in the future seek to broaden the scope of regulation of token sales. This could make token sales subject to registration requirements in the United States and similar jurisdictions. If the METH tokens sale becomes subject to registration requirements, this would delay or potentially postpone the proposed METH token sale indefinitely.

**Taxation Risks**
The use of METH Tokens as a form of currency may or may not be subject to local income tax, capital gain taxes, VAT or other forms of taxes. This uncertainty in tax legislation may expose users and contributors alike to unforeseen future tax consequences associated with the use of METH tokens as a currency, and/or the trading of tokens or METH tokens for capital gains.

**Capital Control Risks**
Many jurisdictions, such as China impose strict controls on the cross-border flow of capital. Holders of METH tokens may be subject to these regulations and/or arbitrary enforcement of such regulations at any time. This would make the transfer of METH out of the local jurisdiction to overseas exchanges an unlawful activity exposing the user of METH to government fines or other regulatory sanction.

**CTF and Anti-Money Laundering Regulations**
The United States has issued a series of regulations to combat terrorist financing (CTF) and money-laundering activities. Many other countries have enacted similar legislation to control the flow of capital for such illicit activities. The use of cryptocurrencies by bad actors would breach such regulations. Any illicit use of METH Tokens could seriously impact the global reputation of the Metha Biofund. In such event, it is conceivable that this could trigger scrutiny by CTF and antimoney laundering regulators and potentially cause significant disruption to the distribution and circulation of METH tokens.
Legal Considerations

Disclaimer
This whitepaper has been prepared by Metha Biofund for the sole purpose of introducing the technical engineering aspects of the METH token sale, its associated platform components, and its underlying blockchain protocol Ethereum. This document does not constitute any offer, solicitation, recommendation or invitation for, or in relation to, the securities of any company described herein. The whitepaper is not an offering document or prospectus, and is not intended to provide the basis of any investment decision or contract. The information presented in this whitepaper is of a technical engineering nature only, and has not been subject to independent audit, verification or analysis by any professional legal, accounting, engineering or financial advisers. The whitepaper does not purport to include information that a buyer of METH might require to form any investment decision, and, in particular, does not comprehensively address risks of METH, which are numerous and significant. Metha Biofund (along with its directors, officers and employees), do not assume any liability or responsibility whatsoever for the accuracy or completeness of information contained in this whitepaper, or for correcting any errors herein. Furthermore, should you choose to participate in the initial sale of METH, Metha Biofund does not assume any liability or responsibility whatsoever for any loss of market value of METH tokens. The content of this whitepaper is technically challenging and requires a high degree of familiarity with distributed ledger technology in order to comprehend METH and its associated engineering risks. Recipients of this document are encouraged to seek external advice, and are solely responsible for making their own assessment of the matters herein, including assessment of risks, and consulting their own technical and professional advisers.

Disclaimer "forward looking statements"
This whitepaper and material uploaded to https://metha.life contain statements related to our future business and financial performance and future events or developments involving Metha Biofund that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Metha Biofund management, of which
many are beyond Metha Biofund control. These are subject to a number of risks, uncertainties and factors, including, but not limited to those described in this whitepaper. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, the actual results, performance or achievements of Metha Biofund may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Metha Biofund neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.